Research programme: tuberculosis therapies - Global Alliance for TB Drug Development

Drug Profile

Research programme: tuberculosis therapies - Global Alliance for TB Drug Development

Alternative Names: NITD304; PA-824 analogues; Pretomanid analogues

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Institute for Tropical Diseases
  • Developer Global Alliance for TB Drug Development
  • Class Amides; Indoles; Nitroimidazoles; Small molecules
  • Mechanism of Action Membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 31 Aug 2017 Discontinued - Preclinical for Tuberculosis in USA (PO)
  • 20 Aug 2014 Novartis Institute for Tropical Diseases grants Global Alliance for TB Drug Development an exclusive global license for all further development and distribution of the tuberculosis therapies programme
  • 27 Jun 2012 Preclinical development is ongoing USA and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top